Opdivo-话题@MedSci

#Opdivo#

81篇内容 | 1472人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1303093, encodeId=a5d51303093e6, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗肝细胞癌，获得FDA的加速批准, objectType=article, longId=189902, objectId=b3c0189902f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3c0189902f2, replyNumber=0, likeNumber=34, createdTime=2020-03-14, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3c0189902f2, moduleTitle=PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗肝细胞癌，获得FDA的加速批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3c0189902f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303092, encodeId=3f911303092e8, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=BMS的PD-1单抗Opdivo首次获批治疗食道癌, objectType=article, longId=188791, objectId=aa9f188e91bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa9f188e91bf, replyNumber=0, likeNumber=30, createdTime=2020-02-27, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa9f188e91bf, moduleTitle=BMS的PD-1单抗Opdivo首次获批治疗食道癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa9f188e91bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303091, encodeId=930c1303091bb, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=百时美施贵宝的PD-1单抗Opdivo组合针对晚期胰腺癌的临床试验失败, objectType=article, longId=188481, objectId=680d18848160, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=680d18848160, replyNumber=0, likeNumber=40, createdTime=2020-02-22, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=680d18848160, moduleTitle=百时美施贵宝的PD-1单抗Opdivo组合针对晚期胰腺癌的临床试验失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=680d18848160)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303090, encodeId=ebd91303090ca, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=CheckMate-025的更新结果显示，在晚期或转移性肾细胞癌患者中，接受PD-1单抗Opdivo治疗的患者在五年后还存活的比例为26％, objectType=article, longId=188280, objectId=62191882804d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62191882804d, replyNumber=0, likeNumber=24, createdTime=2020-02-19, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62191882804d, moduleTitle=CheckMate-025的更新结果显示，在晚期或转移性肾细胞癌患者中，接受PD-1单抗Opdivo治疗的患者在五年后还存活的比例为26％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=62191882804d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303089, encodeId=8112130308979, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=Opdivo联合Yervoy用于先前未治疗的晚期或转移性肾细胞癌患者，在42个月的随访中证明了持续的生存益处, objectType=article, longId=188272, objectId=6dff1882e2d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6dff1882e2d8, replyNumber=0, likeNumber=0, createdTime=2020-02-19, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6dff1882e2d8, moduleTitle=Opdivo联合Yervoy用于先前未治疗的晚期或转移性肾细胞癌患者，在42个月的随访中证明了持续的生存益处, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6dff1882e2d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303088, encodeId=b8f213030884c, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=难治性晚期或复发性卵巢癌患者的III期试验：Opdivo（Nivolumab）未能改善总生存率, objectType=article, longId=186740, objectId=76ac186e40ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76ac186e40ac, replyNumber=0, likeNumber=25, createdTime=2020-01-27, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76ac186e40ac, moduleTitle=难治性晚期或复发性卵巢癌患者的III期试验：Opdivo（Nivolumab）未能改善总生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76ac186e40ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303087, encodeId=5569130308ee4, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=FDA将对PD-1单抗Opdivo联合CTLA-4单抗Yervoy用作非小细胞肺癌的一线治疗，展开优先审查, objectType=article, longId=186455, objectId=16dd186455e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16dd186455e4, replyNumber=0, likeNumber=35, createdTime=2020-01-19, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16dd186455e4, moduleTitle=FDA将对PD-1单抗Opdivo联合CTLA-4单抗Yervoy用作非小细胞肺癌的一线治疗，展开优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16dd186455e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303086, encodeId=dc981303086ec, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=Opdivo & Yervoy联合疗法在日本寻求治疗不可切除、晚期或复发性非小细胞肺癌, objectType=article, longId=185337, objectId=697318533ec4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=697318533ec4, replyNumber=0, likeNumber=31, createdTime=2019-12-29, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=697318533ec4, moduleTitle=Opdivo & Yervoy联合疗法在日本寻求治疗不可切除、晚期或复发性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=697318533ec4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303085, encodeId=a09a130308535, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=Opdivo与Yervoy的联合未能在晚期黑色素瘤研究中达到所有主要终点, objectType=article, longId=183345, objectId=0b1c18334534, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b1c18334534, replyNumber=0, likeNumber=29, createdTime=2019-11-22, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b1c18334534, moduleTitle=Opdivo与Yervoy的联合未能在晚期黑色素瘤研究中达到所有主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b1c18334534)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303084, encodeId=c73c13030845c, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=BMS的Opdivo/Yervoy组合治疗肝细胞癌，获得FDA的优先审查, objectType=article, longId=183122, objectId=309218312237, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=309218312237, replyNumber=0, likeNumber=47, createdTime=2019-11-19, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=309218312237, moduleTitle=BMS的Opdivo/Yervoy组合治疗肝细胞癌，获得FDA的优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=309218312237)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303083, encodeId=9f70130308349, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功, objectType=article, longId=181829, objectId=2a12181829fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a12181829fb, replyNumber=0, likeNumber=29, createdTime=2019-10-25, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a12181829fb, moduleTitle=BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a12181829fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303082, encodeId=5f2c130308223, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=BMS的PD-1单抗Opdivo：未能在III期临床改善多形性胶质母细胞瘤患者的无进展生存期, objectType=article, longId=178992, objectId=cb1b1e899242, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb1b1e899242, replyNumber=0, likeNumber=20, createdTime=2019-09-07, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb1b1e899242, moduleTitle=BMS的PD-1单抗Opdivo：未能在III期临床改善多形性胶质母细胞瘤患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb1b1e899242)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303081, encodeId=61ee130308105, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=与索拉非尼相比，Opdivo无法显著提高肝癌患者的生存率, objectType=article, longId=172162, objectId=ddb51e2162bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddb51e2162bf, replyNumber=0, likeNumber=34, createdTime=2019-06-27, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddb51e2162bf, moduleTitle=与索拉非尼相比，Opdivo无法显著提高肝癌患者的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddb51e2162bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303080, encodeId=4213130308037, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=PD-1单抗Opdivo用作小细胞肺癌的维持免疫疗法，临床试验结果令人失望, objectType=article, longId=164164, objectId=4afe164164c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4afe164164c6, replyNumber=0, likeNumber=0, createdTime=2019-04-14, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4afe164164c6, moduleTitle=PD-1单抗Opdivo用作小细胞肺癌的维持免疫疗法，临床试验结果令人失望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4afe164164c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303079, encodeId=227213030e92c, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=英国NICE批准BMS的肾癌免疫治疗组合：PD-1 单抗Opdivo和CTLA-4 单抗Yervoy, objectType=article, longId=163715, objectId=a607163e15bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a607163e15bb, replyNumber=0, likeNumber=32, createdTime=2019-04-07, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a607163e15bb, moduleTitle=英国NICE批准BMS的肾癌免疫治疗组合：PD-1 单抗Opdivo和CTLA-4 单抗Yervoy, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a607163e15bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303078, encodeId=942913030e8fd, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=Opdivo肺癌长期疗效结果公布，4年总生存达到14%, objectType=article, longId=163619, objectId=b284163619a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b284163619a1, replyNumber=0, likeNumber=31, createdTime=2019-04-06, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b284163619a1, moduleTitle=Opdivo肺癌长期疗效结果公布，4年总生存达到14%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b284163619a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303077, encodeId=103413030e736, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=Opdivo与bempegaldesleukin联合用于一线治疗尿路上皮癌的结果令人满意, objectType=article, longId=160531, objectId=d64716053136, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d64716053136, replyNumber=0, likeNumber=28, createdTime=2019-02-21, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d64716053136, moduleTitle=Opdivo与bempegaldesleukin联合用于一线治疗尿路上皮癌的结果令人满意, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d64716053136)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303076, encodeId=6f6b13030e6e2, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=Opdivo/Yervoy组合显著提高去势抵抗性前列腺癌患者响应率, objectType=article, longId=160436, objectId=dab016043632, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dab016043632, replyNumber=0, likeNumber=35, createdTime=2019-02-20, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dab016043632, moduleTitle=Opdivo/Yervoy组合显著提高去势抵抗性前列腺癌患者响应率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dab016043632)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303075, encodeId=e93113030e5af, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=Opdivo（nivolumab）联合Yervoy（ipilimumab）具有转移性去势抵抗性前列腺癌患者的治疗希望, objectType=article, longId=160343, objectId=61541603433f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61541603433f, replyNumber=0, likeNumber=31, createdTime=2019-02-20, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61541603433f, moduleTitle=Opdivo（nivolumab）联合Yervoy（ipilimumab）具有转移性去势抵抗性前列腺癌患者的治疗希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61541603433f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303074, encodeId=ee5313030e43a, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=百时美施贵宝的PD-1单抗Opdivo未来增长前景堪忧, objectType=article, longId=158911, objectId=f601158911df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f601158911df, replyNumber=0, likeNumber=23, createdTime=2019-01-27, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f601158911df, moduleTitle=百时美施贵宝的PD-1单抗Opdivo未来增长前景堪忧, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f601158911df)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Opdivo

2020-05-29

hb2008ye (审核中...)

前往app查看评论内容

#Opdivo#

PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗肝细胞癌，获得FDA的加速批准

2020-03-14

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

BMS的PD-1单抗Opdivo首次获批治疗食道癌

2020-02-27

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

百时美施贵宝的PD-1单抗Opdivo组合针对晚期胰腺癌的临床试验失败

2020-02-22

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

CheckMate-025的更新结果显示，在晚期或转移性肾细胞癌患者中，接受PD-1单抗Opdivo治疗的患者在五年后还存活的比例为26％

2020-02-19

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

Opdivo联合Yervoy用于先前未治疗的晚期或转移性肾细胞癌患者，在42个月的随访中证明了持续的生存益处

2020-02-19

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

难治性晚期或复发性卵巢癌患者的III期试验：Opdivo（Nivolumab）未能改善总生存率

2020-01-27

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

FDA将对PD-1单抗Opdivo联合CTLA-4单抗Yervoy用作非小细胞肺癌的一线治疗，展开优先审查

2020-01-19

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

Opdivo & Yervoy联合疗法在日本寻求治疗不可切除、晚期或复发性非小细胞肺癌

2019-12-29

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

Opdivo与Yervoy的联合未能在晚期黑色素瘤研究中达到所有主要终点

2019-11-22

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

BMS的Opdivo/Yervoy组合治疗肝细胞癌，获得FDA的优先审查

2019-11-19

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功

2019-10-25

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

BMS的PD-1单抗Opdivo：未能在III期临床改善多形性胶质母细胞瘤患者的无进展生存期

2019-09-07

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

与索拉非尼相比，Opdivo无法显著提高肝癌患者的生存率

2019-06-27

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

PD-1单抗Opdivo用作小细胞肺癌的维持免疫疗法，临床试验结果令人失望

2019-04-14

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

英国NICE批准BMS的肾癌免疫治疗组合：PD-1 单抗Opdivo和CTLA-4 单抗Yervoy

2019-04-07

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

Opdivo肺癌长期疗效结果公布，4年总生存达到14%

2019-04-06

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

Opdivo与bempegaldesleukin联合用于一线治疗尿路上皮癌的结果令人满意

2019-02-21

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

Opdivo/Yervoy组合显著提高去势抵抗性前列腺癌患者响应率

2019-02-20

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

Opdivo（nivolumab）联合Yervoy（ipilimumab）具有转移性去势抵抗性前列腺癌患者的治疗希望

2019-02-20

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

百时美施贵宝的PD-1单抗Opdivo未来增长前景堪忧

2019-01-27

科室
- - 订阅+
  - 更多科室
工具
服务